Axa S.A. Cerevel Therapeutics Holdings, Inc. Transaction History

Axa S.A.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$23.9 - $35.38 $763,533 - $1.13 Million	31,947 Added 15.84%	233,680 $7.43 Million
Q1 2023 May 15, 2023	SELL	$22.82 - $35.32 $10,679 - $16,529	-468 Reduced 0.23%	201,733 $4.92 Million
Q4 2022 Feb 14, 2023	BUY	$25.35 - $31.96 $1.39 Million - $1.75 Million	54,668 Added 37.05%	202,201 $6.38 Million
Q3 2022 Feb 14, 2023	BUY	$25.5 - $41.42 $570,613 - $926,855	22,377 Added 17.88%	147,533 $4.17 Million
Q3 2022 Nov 14, 2022	BUY	$25.5 - $41.42 $570,613 - $926,855	22,377 Added 17.88%	147,533 $4.17 Million
Q2 2022 Feb 14, 2023	SELL	$20.62 - $37.15 $50,189 - $90,423	-2,434 Reduced 1.91%	125,156 $3.31 Million
Q2 2022 Aug 15, 2022	SELL	$20.62 - $37.15 $50,189 - $90,423	-2,434 Reduced 1.91%	125,156 $3.31 Million
Q1 2022 Feb 14, 2023	SELL	$23.5 - $35.38 $468,660 - $705,583	-19,943 Reduced 13.52%	127,590 $4.47 Million
Q1 2022 May 13, 2022	BUY	$23.5 - $35.38 $3 Million - $4.51 Million	127,590 New	127,590 $4.47 Million

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.